Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
RESEARCH TOOLSreports
Top Page
Caris Life Sciences, Inc.
(NASDAQ:CAI)
Rating:51Neutral
Price Target:
$35.00
▼(-8.42% Downside)
Positive Factors
Financial Performance
CAI's first quarter since the IPO was materially ahead of consensus expectations, with stronger pricing and better volumes.
Market Position
Caris Life Sciences is a rapidly-growing market leader in precision oncology lab testing.
Revenue Growth
Revenue of $181.4M well exceeded expectations, growing 81%, with both volumes and Pharma R&D contributing to the strong quarter.
Negative Factors
Profitability Concerns
Caris Life Sciences is initiating with a Buy/High Risk rating due to its attractive growth profile and unique profitability angle.
Stock Volatility
A High Risk rating is assigned due to the current lack of profitability and early-stage commercial payer conversations for rate increases, leading to stock volatility.
Caris Life Sciences, Inc. (CAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.80B
Dividend YieldN/A
Average Volume (3M)713.93K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees1,769
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding281,224,120
10 Day Avg. Volume1,017,826
30 Day Avg. Volume713,933
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.89Price Target Upside-0.86% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Caris Life Sciences, Inc. Business Overview & Revenue Model
Company DescriptionCaris Life Sciences, Inc. is a leading biotechnology company that specializes in molecular intelligence and precision medicine. The company operates primarily in the healthcare sector, focusing on cancer diagnostics and treatment optimization through advanced genomic and proteomic profiling. Caris offers a range of services, including its flagship Caris Molecular Intelligence platform, which provides comprehensive tumor profiling to help healthcare providers determine the most effective therapies for individual patients based on their unique tumor characteristics.
How the Company Makes MoneyCaris Life Sciences generates revenue through the provision of its molecular profiling services to healthcare providers, hospitals, and oncologists. The company charges fees for its tests, which analyze tumor samples to identify genetic alterations and biomarkers that can inform treatment decisions. Key revenue streams include payments for individual tests, subscription models for ongoing services, and partnerships with pharmaceutical companies for drug development and clinical trials. Additionally, Caris may benefit from collaborations with academic institutions and research organizations, which can lead to increased usage of its profiling services in research and clinical practice.
Caris Life Sciences, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 412.26M | 306.13M | 258.49M | 294.01M | 416.54M |
| Gross Profit | 178.78M | 89.31M | 80.02M | 184.16M | 200.51M |
| EBITDA | -182.95M | -260.80M | -245.89M | 201.75M | 228.29M |
| Net Income | -281.89M | -341.42M | -320.83M | 27.73M | 31.01M |
Balance Sheet | |||||
| Total Assets | 343.73M | 412.90M | 717.42M | 2.61B | 2.90B |
| Cash, Cash Equivalents and Short-Term Investments | 66.15M | 121.59M | 409.62M | 132.54M | 46.46M |
| Total Debt | 424.26M | 217.27M | 270.87M | 1.75B | 2.10B |
| Total Liabilities | 2.84B | 2.56B | 2.42B | 1.91B | 2.21B |
| Stockholders Equity | -2.50B | -2.14B | -1.70B | 702.24M | 693.24M |
Cash Flow | |||||
| Free Cash Flow | -253.64M | -298.42M | -327.96M | 57.57M | -65.14M |
| Operating Cash Flow | -245.20M | -276.10M | -285.71M | 277.02M | 254.00M |
| Investing Cash Flow | 52.93M | 214.77M | -282.99M | -33.97M | -271.87M |
| Financing Cash Flow | 200.29M | 10.13M | 10.45M | -249.88M | -108.48M |
Caris Life Sciences, Inc. Risk Analysis
Caris Life Sciences, Inc. disclosed 45 risk factors in its most recent earnings report. Caris Life Sciences, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Caris Life Sciences, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $10.25M | ― | -81.33% | ― | -62.68% | 23.94% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
51 Neutral | $10.80B | ― | ― | ― | ― | ||
40 Underperform | $9.88M | ― | -64.18% | ― | ― | 3.99% | |
37 Underperform | $4.38M | ― | -2151.29% | ― | 76.98% | -52.89% | |
34 Underperform | $10.17M | ― | -165.56% | ― | ― | 58.67% | |
| ― | $7.70M | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CAI
Caris Life Sciences, Inc.
38.22
10.97
40.26%
INAB
IN8bio
2.28
-13.30
-85.37%
MSPR
MSP Recovery
0.45
-5.41
-92.32%
NLSP
NLS Pharmaceutics
2.22
-3.82
-63.25%
SNSE
Sensei Biotherapeutics
8.02
-4.18
-34.26%
BOLT
Bolt Biotherapeutics
5.35
-8.45
-61.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.